Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Operating Expenses (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Operating Expenses for 16 consecutive years, with $40.9 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 30.73% to $40.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $197.6 million through Dec 2025, down 23.48% year-over-year, with the annual reading at $197.6 million for FY2025, 23.48% down from the prior year.
  • Operating Expenses hit $40.9 million in Q4 2025 for Ironwood Pharmaceuticals, down from $46.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $1.2 billion in Q2 2023 to a low of $38.6 million in Q3 2021.
  • Historically, Operating Expenses has averaged $109.3 million across 5 years, with a median of $45.3 million in 2023.
  • Biggest five-year swings in Operating Expenses: surged 2763.48% in 2023 and later crashed 94.17% in 2024.
  • Year by year, Operating Expenses stood at $60.5 million in 2021, then plummeted by 35.85% to $38.8 million in 2022, then surged by 105.9% to $80.0 million in 2023, then dropped by 26.15% to $59.1 million in 2024, then tumbled by 30.73% to $40.9 million in 2025.
  • Business Quant data shows Operating Expenses for IRWD at $40.9 million in Q4 2025, $46.6 million in Q3 2025, and $39.9 million in Q2 2025.